Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of SPD417 in treating bipolar
manic symptoms, when given once daily in the evening vs. twice daily.